tradingkey.logo
tradingkey.logo
Search

bioAffinity Technologies Inc

BIAF
Add to Watchlist
0.778USD
-0.011-1.37%
Close 07/09, 16:00ETQuotes delayed by 15 min
4.89MMarket Cap
LossP/E TTM

TradingKey Stock Score of bioAffinity Technologies Inc

Currency: USD Updated: 2026-07-09

Key Insights

bioAffinity Technologies Inc's fundamentals are relatively healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 141 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

bioAffinity Technologies Inc's Score

Industry at a Glance

Industry Ranking
141 / 203
Overall Ranking
355 / 4560
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

bioAffinity Technologies Inc Highlights

StrengthsRisks
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.32% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.16M.
Overvalued
The company’s latest PE is -0.17, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 291.72K shares, increasing 2.46% quarter-over-quarter.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
6.000
Target Price
+2190.95%
Upside Space

FAQs

How does TradingKey generate the Stock Score of bioAffinity Technologies Inc?

The TradingKey Stock Score provides a comprehensive assessment of bioAffinity Technologies Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of bioAffinity Technologies Inc’s performance and outlook.

How do we generate the financial health score of bioAffinity Technologies Inc?

To generate the financial health score of bioAffinity Technologies Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects bioAffinity Technologies Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of bioAffinity Technologies Inc.

How do we generate the company valuation score of bioAffinity Technologies Inc?

To generate the company valuation score of bioAffinity Technologies Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare bioAffinity Technologies Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of bioAffinity Technologies Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of bioAffinity Technologies Inc.

How do we generate the earnings forecast score of bioAffinity Technologies Inc?

To calculate the earnings forecast score of bioAffinity Technologies Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on bioAffinity Technologies Inc’s future.

How do we generate the price momentum score of bioAffinity Technologies Inc?

When generating the price momentum score for bioAffinity Technologies Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of bioAffinity Technologies Inc’s prices. A higher score indicates a more stable short-term price trend for bioAffinity Technologies Inc.

How do we generate the institutional confidence score of bioAffinity Technologies Inc?

To generate the institutional confidence score of bioAffinity Technologies Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about bioAffinity Technologies Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of bioAffinity Technologies Inc.

How do we generate the risk management score of bioAffinity Technologies Inc?

To assess the risk management score of bioAffinity Technologies Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of bioAffinity Technologies Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of bioAffinity Technologies Inc.
tradingkey.logo
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.